Preface

Excerpt

Although urothelilal carcinoma is a significant health threat to the U.S. population, integrated clinical and laboratory investigations of this disease have lagged behind those of other forms of cancer. Rapid advances in our understanding of cancer biology have not been translated into improved patient care. Ongoing interactions between clinical investigators and laboratory scientists who study genitourinary malignancies are crucial to accelerate this progress as increased understanding of the genetic and molecular mechanisms underlying the genesis of bladder cancer will lead to the development of molecular markers of risk, progression and therapeutic response and early stage clinical trials of promising novel therapeutic agents based on this information. We also encourage industry’s continued participation in the process. …